PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21029677-1	2010	OBJECTIVE: To study the effect of pioglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the RANKL-mediated osteoclastogenesis of osteoclast precursor cells, and to explore the function and mechanism of PPARgamma in the osteoclast differentiation.	Pioglitazone	34-46	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	137-142	
27430581-0	2016	Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.	Pioglitazone	0-12	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	29-34	
27430581-3	2016	The present study aimed to investigate the effect of pioglitazone (PIO), a thiazolidinedione, on osteoblastogenesis, osteoclastogenesis and the osteoprotegerin (OPG) / receptor activator of nuclear factor-kappaB ligand (RANKL) / RANK system.	Pioglitazone	53-65	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	220-225	
21029677-4	2010	And pioglitazone treated cells were exposed to 10 micromol/L pioglitazone during the process of osteoclast differentiation under RANKL.	Pioglitazone	4-16	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	129-134	
21029677-4	2010	And pioglitazone treated cells were exposed to 10 micromol/L pioglitazone during the process of osteoclast differentiation under RANKL.	Pioglitazone	61-73	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	129-134